Shukra Pharmaceuticals Share Price

CMP as on23-Sep-20 9:44

₹ 51.70
2.4 4.87%

Open

₹ 49.30

Turnover (lac)

Prev. Close

₹ 49.30

Day's Vol (shares)

₹ 105

Day's Range

₹ 49.30
₹ 51.70

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 08-Sep-2020 - -
Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/09/2020 ,inter alia, to consider and approve The meeting of the Board of Directors of the Company will be held on 15th September, 2020 at 02:00 p.m. at the Registered Office of the Company to transact the following business: 1. To consider, adopt and approve Unaudited Financial Results for the quarter ended on 30th June, 2020. 2. Any other business with the permission of the Chair. Please take the same on record.
Board Meeting - 24-Jul-2020 - -
Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2020 ,inter alia, to consider and approve transact the following business: 1.To Approve the standalone Audited Financial Results for the Quarter and Year ended on 31st March, 2020 along with the Auditors Report and Certificate for unmodified opinion Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. 2.To review the business of the company. 3.Any other business with the permission of chair. With reference to above subject and in Compliance with the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company at its meeting held today, i.e. 30th July, 2020 at 11:00 A.M. and concluded on 10 :40 P.M. at its registered Office, inter-alia, transacted the following businesses: 1)Considered, approved and adopted the Audited Standalone Financial Results for the Quarter and Year ended on 31st March, 2020 along with the Auditors Report and Certificate for unmodified opinion Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. 2)Reviewed the business of the company. Please take the same on your records and oblige. (As per BSE Announcement Dated on 30/07/2020)
Board Meeting - 16-Mar-2020 - -
Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/03/2020 ,inter alia, to consider and approve the following business: 1. To Appoint Mr. Mehul Patel as Chief Financial Officer (KMP) of the Company. 2. To Appoint Mr. Ashvin Trivedi (DIN: 03212457) as an additional Non-executive director of the Company. 3. Any other business with the permission of the chair. With reference to above subject and in compliance with the SEBI (Listing Obligation. and Disclosure Requirements) Regulation, 2015 we hereby inform your good office that, due to COVID-19 and implementation of Section 144 of the Criminal Procedure Code (CrPC) of 1973 along with lock down of Ahmedabad City, holding of meeting of Board of Directors of the company could not be possible and hence adjourned till further notification from the concerned regulatory body of the government for removing all restrictions. (As Per BSe Announcement Dated 25.03.2020) (Revised) A meeting of the Board of Directors is rescheduled will be held on 11th, May, 2020 inter alia, to transact thefollowing business: 1. To Appoint Mr. Mehul Patel as Chief Financial Officer [KMP) of the Company 2. To Appoint Mr. Ashvin Trivedi [DIN: 03212457) as an additional Non-executive director of the Company. 3, To appoint Ms. Rupal Patel, Practising company Secretary as Secretarial Auditor of the Company for the F.Y-20t9-20. 4. To appoint M/s. Soni & Patel, Chartered Accountants as Internal Auditor of the Company. 5. To Accept and take note of Resignation of Mr. Karnik Shah as chief Executive officer (CEO) of the Company. 6. Review the Business Operations of the Company. 7. Any other business with the permission of the Chair. (As per BSE Bulletin Dated on 04/05/2020) Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/05/2020 ,inter alia, to consider and approve Notice is hereby given that pursuant to the Regulation 29 read with other applicable Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, a meeting of the Board of Directors of the Company is rescheduled will be held on 11th May, 2020 at 04:00 p.m. at the Registered Office of the Company to transact the following business: 1. To Appoint Mr. Mehul Patel as Chief Financial Officer [KMP) of the Company. 2. To Appoint Mr. Ashvin Trivedi [DIN: 03212457) as an additional Non-executive director of the Company. 3. To appoint Ms. Rupal Patel, Practising Company Secretary as Secretarial Auditor of the Company for the F.Y. 2019-20. 4. To appoint M/s. Soni & Patel, Chartered Accountants as Internal Auditor of the Company. 5. To Accept and take note of Resignation of Mr. Karnik Shah as Chief Executive Officer (CEO) of the Company. 6. Review the Business Operations of the Company. 7. Any other business with the permission of the Chair. (As Per BSE Announcement dated on 04.05.2020) Shukra Pharmaceuticals Ltd has informed BSE about Outcome of Board Meeting held on May 11, 2020. (As Per BSE Announcement Dated on 5/11/2020 5:56:42 PM) 1. Appointment of Mr. Mehul Patel as Chief Financial Officer [KMP) of the Company. 2. Appointment of Mr. Ashvin Trivedi [DIN: 03212457) as an additional Non-executive director of the Company. (As Per BSE Announcement Dated on 12.05.2020)
Board Meeting - 05-Mar-2020 - -
Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/03/2020 ,inter alia, to consider and approve Notice is hereby given that pursuant to Regulation 25 of SEBI (Listing obligation and Disclosure Requirement) Regulation, 2015 and Schedule IV, Clause VII of companies act, 2013 that a separate meeting of the Independent Directors of the Company will be held on Saturday, 14th March 2020 at 01: 00 noon at the registered office of the Company to transact the following business: 1) To review the performance of non- independent directors and the Board as a whole. 2) To review the performance of the chairperson of the company, taking into account the views of executive directors and non-executive directors. 3) To Evaluated the Quantity, Quality and timeliness of flow of information between the Company management and Board in line with the requirement of Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with applicable provisions of Schedule IV of the Companies Act, 2013. 4) Any other business with the permission of the chair. With reference to the above cited subject, we would like to inform you that separate meeting of the Independent Directors of the Company held today i.e 01:00 P.M. and Concluded at 01:45 P.M. the following business were transacted: 1.Review the performance of non- independent directors and the Board as a whole. 2.Review the performance of the chairperson of the company, taking into account the views of executive directors and non-executive directors. 3.Assessed the quality, quantity and timeliness of the flow of information between the Company management and the Board that is necessary for the Board to perform their duties. (As Per BSE Announcement Dated 14.03.2020)
Board Meeting - 04-Feb-2020 - -
Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2020 ,inter alia, to consider and approve 1. To consider, adopt and approve Unaudited Financial Results for the quarter ended on 31st December, 2019. 2. Any other business with the permission of the Chair. With reference to above subject and in compliance with the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. 14th February, 2020 at 03.00 p.m. and concluded at 08.00 p.m.:- 1. Considered, adopted and approved Unaudited Financial Results for the quarter ended on 31st December, 2019. (As Per BSE Announcement Dated on 14/02/2020) With reference to above subject and in compliance with the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on 14th February, 2020 for Considered, adopted and approved Unaudited Financial Results along with Limited Review Report for the quarter ended on 31st December, 2019 as per mail received from BSE on 25th February, 2020. (As Per BSE Announcement dated on 27.02.2020)
Board Meeting - 03-Dec-2019 - -
Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/12/2019 ,inter alia, to consider and approve 1. To appointment of Ms. Arpita Shah (Membership No. 60451), as Company Secretary and Compliance officer of the Company. 2. Any other business with the permission of the Chair. we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. 07th December, 2019 at 11:00 a.m. and concluded on 04:00 p.m. 1) Appointment of Ms. Arpita Shah (Membership No. 60451), as Company Secretary and Compliance officer of the Company. 2) Appointment of Nodal Officer as Ms. Arpita Shah for the purpose of co-ordination with IEPF Authority. (As Per BSE Announcement Dated on 07.12.2019)
Board Meeting - 06-Nov-2019 - -
Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2019 ,inter alia, to consider and approve 1. To consider, adopt and approve Unaudited Financial Results for the quarter ended on 30th September, 2019. 2. Any other business with the permission of the Chair. With reference to above subject and in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. 13th November, 2019 at 03:00 p.m. and concluded on 10.15 p.m. 1) Considered, adopted and approved Unaudited Financial Results for the quarter and half year ended on 30th September, 2019. Please take the same on record. Thanking you, (As Per BSE Announcement Dated 13.11.2019)